SUPER $TOCKS DD and RESEARCH FORUM

[JMcWhirter]

$OBMP therapeutic cancer vaccine for prostate cancer patients using similar techniques developed for breast cancer patients.

The PPS last year was .32 and is now under .016
Last year the company was only at Phase I and now they are in Phase II Trails.

OncBioMune Selects Theradex as CRO for Two Phase 2 Trials of ProscaVax for Prostate Cancer
https://www.otcmarkets.com/stock/OBMP/news/OncBioMune-Selects-Theradex-as-CRO-for-Two-Phase-2-Trials-of-ProscaVax-for-Prostate-Cancer?id=185610

ProscaVax – Prostate Cancer

"The Company incorporates scientifically proven and clinically validated treatments for cancer. We utilize patented technology developed and or acquired by OncBioMune. The intellectual property consists of multiple technologies combined with laboratory and clinical procedures that provide new insight into the treatment of cancer. The Company’s proprietary technology provides the necessary tools for the successful treatment of patient’s with a therapeutic vaccine. It is marketable and would be very profitable upon FDA approval.

Information on the current clinical trial of ProscaVax can be found on the clinictrials.gov at https://clinicaltrials.gov/ct2/show/NCT02058680?term=oncbiomune&rank=1.

OvcaVax - Breast Cancer


We developed our vaccine in 1993 and then immediately began vaccinating patients with depressed immunity. We obtained the first patent on a breast cancer vaccine in the U.S.A. in 1994, and were the first to use the cytokines GM-CSF and IL-2 as biological adjuvants. Appropriate patients are vaccinated in the adjuvant setting and patients with advanced disease are treated with a combined chemo-immunotherapy protocol. Some of these patients have had dramatic responses.